《接受贝伐珠单抗治疗的卵巢癌和宫颈癌患者血压管理专家共识》:2019英国专家建议解读  

Interpretation of 2019 UK Expert Recommendations on the Management of Hypertension in Patients with Ovarian and Cervical Cancer Receiving Bevacizumab

作　　者：唐欣颖 匡泽民[2] TANG Xin-ying;KUANG Ze-min(Department of Cardiology,The First People's Hospital of Chenzhou,the University of South China,Chenzhou 423000,China;Department of Hypertension,Beijing Anzhen Hospital Affiliated to the Capital Medical University,Beijing 100029,China)

机构地区：[1]南华大学附属郴州市第一人民医院心血管内科,郴州423000 [2]首都医科大学附属北京安贞医院高血压科,北京100029

出　　处：《中国合理用药探索》2020年第1期11-15,共5页Chinese Journal of Rational Drug Use

基　　金：中国中青年临床研究基金(2017-CCA-VG-016);北京市卫生与健康科技成果和适宜技术推广项目(2018-TG-03);首都医科大学附属北京安贞医院院长科技发展基金(2016P01);李氏大药厂科研基金项目(2016)

摘　　要：贝伐珠单抗是新型的靶向抗肿瘤药物,主要用于晚期、转移性或复发性非小细胞肺癌、转移性结直肠癌患者的治疗。贝伐珠单抗通过与人血管内皮生长因子(VEGF)结合,抑制VEGF与其受体结合,阻断血管生成的信号通路途径,抑制肿瘤细胞生长,但药源性高血压是其常见的不良反应。近期,英国专家对接受贝伐珠单抗治疗患者的血压管理达成共识。本文就共识的重点和亮点进行解读,旨在为医生临床使用贝伐珠单抗治疗前、治疗中和治疗后,提供针对性的血压管理指导。Bevacizumab is a new type of targeted anti-tumor drug,which is mainly used in the treatment of patients in advanced stage,or with metastatic or recurrent non-small cell lung cancer or metastatic colorectal cancer.Bevacizumab inhibits the growth of tumor cells by binding to human vascular endothelial growth factor(VEGF),it inhibits the binding of VEGF and its receptors and blocks the angiogenesis signal pathway.However,drug-induced hypertension is a common adverse reaction.Recently,UK experts reached consensus on management of hypertension in patients receiving bevacizumab.This paper interprets the key points and highlights of the consensus.The aim is to provide physicians with targeted guidance on management of hypertension before,during and after receiving bevacizumab.

关 键 词：贝伐珠单抗 药源性高血压 血压管理 专家共识 解读 

分 类 号：R979.1[医药卫生—药品]